News & Blogs

Commitment to Seniors Opposes Draft Regulations Under the Comprehensive Outbound Investment National Security (COINS) Act

Washington, D.C. – October 22, 2026 – Commitment to Seniors (C2S), a project of American Commitment, opposes the U.S. Treasury Department’s draft regulations under the Comprehensive Outbound Investment National Security (COINS) Act, which would expand restrictions on outbound investment in biopharmaceuticals. American seniors have the most to lose when government policies stand in the way of medical progress. Treasury’s proposed expansion of investment restrictions threatens to do exactly that. By preventing American companies from pursuing…

Learn More

Beware the Post-Midterm Price Control Creep

Storm clouds are gathering for Republicans ahead of next month’s midterm elections. If the forecast holds, a divided government could leave Washington gridlocked for two years. Yet one policy idea being floated on Capitol Hill may find support from both congressional Democrats and the White House during the stalemate. For those who favor limited government and competitive markets, the prospect is unnerving. In 2022, President Joe Biden and his allies in Congress passed the Inflation…

Learn More

Buyer Beware: New Medicare Plans Have Fewer Benefits, Higher Costs

It is going to be a tough year for seniors shopping for Medicare coverage. If you don’t choose wisely, you might get hit with surprise bills for your medications, or learn too late that your doctors are out of network. For the third year in a row, major Medicare insurers are pruning some benefits while adding bigger out-of-pocket charges such as deductibles. “Medicare Advantage plans are leaning toward focusing on margin repair,” said Michael Ha,…

Learn More

Most Favored Nation Price Controls Disfavor Patients

President Trump recently boasted that all 50 state Medicaid programs, along with the DC and Puerto Rico programs, are now using Most Favored Drug (MFN) pricing. MFN pricing requires pharmaceutical companies to charge American consumers a price equal to or below the lowest price they charge one of 19 reference countries. MFN is a response to the longstanding complaint that Americans pay more for pharmaceuticals made by American companies than consumers in other countries. One…

Learn More

Commitment to Seniors Opposes CMMI’s Final Rule for GLOBE Drug Pricing Model

Washington, D.C. – October 1, 2026 – Commitment to Seniors (C2S), a project of American Commitment, opposes the final rule for the Global Benchmark for Efficient Drug Pricing (GLOBE) model from the Centers for Medicare and Medicaid Innovation (CMMI). This model effectively imposes price controls on the American health care market by tying U.S. drug prices to prices set by foreign governments. Importing foreign price controls risks American jobs, undermines U.S. leadership in pharmaceutical innovation,…

Learn More

Emulating European healthcare won’t win America the biotech race

As Washington debates new ways to make the nation’s healthcare system work better for Americans, policymakers should keep one question in mind: What would happen if the U.S. stopped being the world’s most attractive place to discover and develop new medicines? The answer is not theoretical. Europe already ran that experiment. For decades, the United States has been the global leader in medical innovation. American researchers, universities, investors and life sciences companies have produced treatments…

Learn More

Medicare Advantage plans shift more costs onto seniors in 2027

People who have a Medicare Advantage plan — and wind up needing care and prescriptions next year — are in for a rude awakening. Medicare Advantage insurers are raising out-of-pocket costs for enrollees, drastically cutting money for dental work and other benefits, and eliminating plans that have broad networks of hospitals and doctors, according to federal data released this week and analyzed by STAT and several investment firms. That could result in more shock for…

Learn More

AARP’s $200 billion mirage: How price controls kill tomorrow’s medicine

AARP, the liberal lobbying organization that touts itself as America’s leading senior advocacy group, wants Democrats to greatly expand the Inflation Reduction Act’s drug price controls if they retake Congress and the White House. To spur left-wing lawmakers into action, AARP recently released a report with an eye-popping conclusion: If Democrats change the IRA to add price controls on just 10 popular medicines that are currently exempt, it could save Medicare nearly $200 billion between…

Learn More